MedPath

GeneMedicine Co., Ltd.

🇰🇷South Korea
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

Phase 1
Recruiting
Conditions
Renal Cell Carcinoma
Colorectal Cancer
Head and Neck Cancer
Malignant Melanoma
Breast Cancer
Cervical Cancer
Interventions
Drug: GM103 (Part A)
Drug: GM103 (Part B)
First Posted Date
2024-02-20
Last Posted Date
2024-03-21
Lead Sponsor
GeneMedicine Co., Ltd.
Target Recruit Count
125
Registration Number
NCT06265025
Locations
🇰🇷

National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of

🇰🇷

Korea University Anam Hospital, Seoul, Korea, Republic of

🇰🇷

Hanyang University Seoul Hospital, Seoul, Korea, Republic of

and more 1 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.